Summary of opinion: Kevzara, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Kevzara, 14/11/2024 Positive
Summary of opinion: Sarclisa, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Sarclisa, 14/11/2024 Positive
Summary of opinion: Jakavi, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Jakavi, 14/11/2024 Positive
Summary of opinion: CellCept, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: CellCept, 14/11/2024 Positive
Summary of opinion: Evkeeza, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Evkeeza, 14/11/2024 Positive
Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
Summary of opinion: Tagrisso, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Tagrisso, 14/11/2024 Positive
Summary of opinion: Rybrevant, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Rybrevant, 14/11/2024 Positive
EMA encourages companies to submit type I variations for 2024 by end November 2024
Submitted by Anonymous (not verified) on 15 November 2024 - 10:30
EMA encourages companies to submit type I variations for 2024 by end November 2024
Expert reports on big data related topics
Submitted by Anonymous (not verified) on 15 November 2024 - 9:15
Expert reports on big data related topics